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Abstract
As the life expectancy of people living with HIV improves as a result of antiretroviral therapy, increasing numbers of women
living with HIV (WLHIV) are now reaching menopausal age. The menopause transition in WLHIV remains a relatively
overlooked area in clinical HIV research. Whilst there is some evidence to suggest that WLHIV experience menopause at
an earlier age and that they have more menopausal symptoms, there is no clear consensus in the literature around an
impact of HIV infection on either timing or symptomatology of the menopause. Data are also conflicting on whether
HIV-related factors such as HIV viral load and CD4 cell count have an impact on the menopause. Furthermore, menopausal
symptoms in WLHIV are known to go under-recognised by both healthcare providers and women themselves.
There is likely to be a burden of unmet health needs among WLHIV transitioning through the menopause, with significant
gaps in the evidence base for their care. With this in mind, we have developed the PRIME study (Positive Transitions
Through the Menopause). This mixed-methods observational study will explore, for the first time in the UK, the impact
of the menopause on the health and wellbeing of 1500 ethnically diverse WLHIV. In establishing a cohort of women in
their midlife and following them up longitudinally, we hope to develop a nuanced understanding of the gendered aspects
of ageing and HIV, informing the provision of appropriate services for WLHIV to ensure that they are supported in maintaining
optimal health and wellbeing as they get older.
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Introduction
Of the 37 million people currently living with HIV globally, half
are women (www.unaids.org, accessed 07 January 2016). Despite
this, there remains a paucity of data relating to the reproductive
and post-reproductive health of women living with HIV (WLHIV)
[1].
Improvements in survival due to antiretroviral therapy (ART) have
resulted in successfully treated HIV-positive individuals now having
a near normal life expectancy, and a shift in the age distribution
of people living with HIV [2,3]. The transformation of HIV into a
chronic medical condition means that co-morbid conditions and
other age-related events are now of increasing importance in
clinical HIV practice; among women, these events include the
menopause. Approximately 8700 women of potentially menopausal
age (between 45 and 56) attended for HIV-related care in the
UK in 2014, a six-fold increase over a 10-year period (Z Yin, Public
Health England, personal communication). Based on the age
distribution of HIV-positive women attending for HIV care in 2013,
a total of 10,000 women are likely to reach potentially menopausal
age in the next 10 years (Z Yin, Public Health England, personal
communication) [4].
Overview of natural menopause
Natural menopause is defined as ‘the permanent cessation of
menstruation resulting from the loss of ovarian follicular activity’,
in the absence of other physiological or pathological causes [5].
The average age at natural menopause in the UK is 52 years [6],
although there is considerable geographical variation, with age
at natural menopause lowest among women from African, Latin
American, Asian and Middle Eastern countries [7]. The transition
to menopause is often accompanied by a range of physical and
psychological changes, with 85% of women reporting symptoms
such as hot flushes, sleep disturbance or mood changes [8].
According to a recent large American cohort study, the median
duration of vasomotor symptoms is longer than previously thought
at 7.4 years, continuing for an average of 4.5 years beyond final
menstrual period [9]. However, it is important to note that the
menopause is a complex biosocial phenomenon, where factors such
as ethnicity and socioeconomic status affect reporting, duration
and experience of symptoms [9–11]. Despite this variation across
sociocultural contexts, menopausal symptoms have consistently
been shown to impact negatively upon women‘s perceived health,
their quality of life, and their role performance both at work and
within relationships [12–14].
HIV and the menopause
There are several reasons why we may expect the menopause
transition to be different in WLHIV. First, gonadal dysfunction is
well-described in men living with HIV, even in the highly active
antiretroviral therapy (HAART) era [15]. Gonadal function is
relatively understudied in WLHIV, however, an analysis of data from
the Women‘s Interagency HIV Study (WIHS) found that HIV-
positive women were more likely to have lower levels of anti-
mullerian hormone (a biological marker of ovarian reserve), largely
explained by lower CD4 counts [16]. The pathophysiology
underlying ovarian dysfunction in WLHIV is likely to be similar to
that underlying hypogonadism in men, with possible factors
including the effects of opportunistic infection and the virus itself
on the ovaries and the pituitary gland [15]. Furthermore, given
that HIV is increasingly understood to be associated with persistent
inflammation, we can hypothesise that this may affect the
neuroendocrine axis. HIV-related effects on the ovaries or
neuroendocrine axis may alter both the natural history and
symptomatology of menopause in WLHIV, especially in the context
of other contributing factors such as substance misuse, lower
socioeconomic status and non-Caucasian ethnicity.
Secondly, there may be an additive effect of oestrogen depletion
to the already increased risk of dyslipidaemia, osteoporosis and
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cardiovascular disease in WLHIV [17]. Finally, transitioning through
the menopause in the context of chronic illness may present
difficulties in determining aetiology of symptoms, with evidence
suggesting that menopausal symptoms in WLHIV go under-
recognised by both healthcare providers [18] and women
themselves [19]. Moreover, WLHIV face the additional challenge
of managing menopausal symptoms whilst living with a chronic
illness requiring careful management and monitoring.
Current evidence
Data on the association between HIV and earlier age at menopause
is conflicting. Several studies, including one of the very few to
be conducted in Europe, have reported a median age at
menopause younger than 52, with ages ranging from 47.5 to 50
years, suggesting that WLHIV may transition through menopause
at an earlier age than their HIV-negative counterparts [20–25].
However, the only studies including an HIV-negative comparison
group have reported similar ages at menopause in both HIV-
positive and HIV-negative women [25,26]. In terms of predictors
of age at menopause in WLHIV, again data are conflicting with
some authors reporting no association between age at menopause
and HIV-related factors such as HIV viral load, CD4 cell count and
the use of ART [20,22], and others reporting current low CD4 cell
count as a risk factor [24,26,27].
Relatively few studies exist on the symptomatology of the
menopause in WLHIV. Lui-Filho et al. [28] reported no association
between HIV status and a range of menopausal symptoms
including hot flushes and vaginal dryness. However, other authors
have reported that HIV-positive serostatus is associated with
increased menopausal symptoms including hot flushes [29], other
vasomotor symptoms [20,23], sexual dysfunction [20], and mood
changes [23,30]. Again, there is little consensus on the relationship
between cell count and HIV viral load, and menopausal symptoms
with two studies reporting no association [21,29] and others
demonstrating an association between higher CD4 cell count and
increased vasomotor symptoms [28,31].
Finally, given the immunomodulatory effects of oestrogen, the
impact of the menopause transition and consequent oestrogen
depletion on the natural history of HIV is of interest. However,
only three studies have looked at this, finding no evidence of an
effect of menopausal status on either CD4 cell count decline after
HIV seroconversion [32], or response to ART [33,34].
Gaps in evidence
In view of the conflicting literature on HIV and both natural history
and symptomatology of the menopause, further research is
warranted in this area. Of note, the overwhelming body of work
has emerged from the United States and South America. Findings
from these studies may not be applicable in settings such as
sub-Saharan Africa and Europe, where patient cohorts may differ
in terms of ethnicity, comorbidity, substance misuse, socioeconomic
status and healthcare access.
Current UK guidelines on management of the menopause
recommend that menopausal women be given adequate
information on symptomatology, lifestyle modification and
treatment options including hormone replacement therapy (HRT)
[35]. HRT can be offered to allevitate vasomotor symptoms and
low mood that arise as a result of the menopause [34]. However,
there are notable gaps in the evidence base around the clinical
support required for WLHIV experiencing the menopause transition.
This includes a lack of information on: long-term safety and
efficacy of HRT; drug interactions between HRT and ART; the
potential role of psychosocial interventions; and the impact of the
menopause transition on WLHIV’s quality of life and their ability
to engage with health-sustaining behaviours such as adherence
to ART and retention in HIV care. Finally, there remains an absence
of qualitative literature on women‘s experience of reproductive
ageing in the context of HIV.
The PRIME study
With these gaps in mind, we designed the PRIME study (Positive
Transitions Through the Menopause, www.ucl.ac.uk/prime-study),
a mixed-methods observational study funded by the UK‘s National
Institute of Health Research (NIHR). Our overarching aim is to
explore, for the first time in the UK, the impact of the menopause
on the health and wellbeing of WLHIV. The specific objectives of
the study are (amongst WLHIV):
1. To estimate the prevalence of menopause (stratified by age)
and menopausal symptoms.
2. To explore factors associated with earlier age at menopause
and increased menopausal symptoms.
3. To explore the association between both menopausal status
and symptoms, and: (i) mental health, (ii) sexual function,
(iii) quality of life, (iv) adherence to ART, (v) attendance for
HIV care, and (vi) condom use.
4. To explore the mechanisms by which the menopause may
impact upon engagement with HIV care and wellbeing.
5. To describe the current management of menopausal
symptoms in the UK and identify areas of clinical need.
We aim to recruit 1500 WLHIV aged between 45 and 60 from
National Health Service (NHS) HIV clinics across the UK. The study
comprises self-completed paper questionnaires, collection of clinical
data, and semi-structured interviews with a proportion of women.
Furthermore, we are seeking consent for ongoing follow-up,
thereby establishing a unique cohort of ethnically diverse women
ageing with HIV. This will allow the longitudinal study of the effects
of ageing, specifically the menopause, on the longer-term health
and wellbeing of WLHIV.
Conclusion
There remains a paucity of data on HIV and the menopause,
particularly within Europe and sub-Saharan Africa. Whilst there
is some evidence to suggest that WLHIV experience menopause
at an earlier age and that they experience a greater symptom
burden than women without HIV, there is no clear consensus
around the impact of HIV on either timing or symptomatology
of the menopause in the literature. Little is known about predictors
of menopausal symptoms within this group, nor of the impact of
menopausal symptoms on women‘s wellbeing and ability to engage
with health-sustaining behaviours. Furthermore, menopausal
symptoms in WLHIV may be under-recognised by healthcare
providers and by women themselves, and there are few data on
symptom management within this population.
There is likely to be a burden of unmet health needs among
WLHIV women transitioning through menopause. The PRIME
Study is a mixed-methods observational study that will allow
exploration of the impact of the menopause on health and
wellbeing among an ethnically diverse cohort of WLHIV in the
UK. We hope that this study will contribute to a more nuanced
understanding of the gendered aspects of ageing and HIV,
informing the provision of appropriate services for WLHIV to
ensure that they are supported in maintaining optimal health
into their post-reproductive years.
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